Michael F. Moloney
Keine laufenden Positionen mehr
Profil
Michael F.
Moloney served as Vice President-Information Systems & Technology at BioNumerik Pharmaceuticals, Inc. from 2000 to 2006.
He also served as Chief Operating Officer at OncoVista Innovative Therapies, Inc. from 2011 to 2014.
Moloney received his undergraduate degree from Alderson-Broaddus College and his MBA from The University of Texas at Austin.
Ehemalige bekannte Positionen von Michael F. Moloney
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOVISTA INNOVATIVE THERAPIES, INC. | Geschäftsführer | 11.02.2014 |
BioNumerik Pharmaceuticals, Inc.
 BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2006 |
Ausbildung von Michael F. Moloney
| Alderson-Broaddus College | Undergraduate Degree |
| The University of Texas at Austin | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ONCOVISTA INNOVATIVE THERAPIES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
BioNumerik Pharmaceuticals, Inc.
BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Health Technology |